Early lab studies have shown inactivated vaccines developed by Chinese companies Sinovac and Sinopharm elicited less protective antibodies against the omicron variant than mRNA vaccines from Pfizer
Moderna Inc on late Thursday sought emergency use authorization with US health regulators for a second Covid booster shot, as a surge in cases in some parts of the world fuels fears of another wave
Torrent Pharma and Cadila Pharma sign licensing agreement with MPP to make and market the drug
Pharma firms enter into licensing agreement with Medicine Patent Pool to use nirmatrelvir compound for making PAXLOVID
Generic drugmakers across a dozen countries in Asia, the Caribbean, the Middle East and Eastern Europe will begin producing either the raw ingredients for the Pfizer drug or the pill itself.
Drugmaker Pfizer is expected to request authorisation this week for an additional Covid-19 booster dose for seniors, according to a person familiar with the matter.
Two doses of Pfizer-BioNTech Covid-19 vaccine greatly reduced the risk of Omicron infection among children aged five to 15, according to a study published by the US CDC.
The Pfizer-BioNTech vaccine was previously granted a green light for use in children aged five and over last November
The study examined Pfizer vaccine effectiveness from December 13, 2021 to January 30, 2022, among 852,384 fully-vaccinated children 12-17 years and 365,502 children 5-11 years
Moderna chief executive Stephane Bancel said in an interview the company aimed to have a booster ready by August 2022, before next autumn when he said more vulnerable people may need it
The findings, published in the journal Nature, suggest that declining antibody levels in the months after vaccination primarily represent a shift to a sustainable immune response
The pill is a small-molecule oral drug, a co-package of antiviral drugs nirmatrelvir tablets and ritonavir tablets, for adults who are experiencing mild to moderate Covid symptoms
The US FDA) announced that it has postponed an advisory panel meeting on the use of the Pfizer-BioNTech Covid-19 vaccine in children six months through four years of age, saying it needs more data.
Japan has granted fast-track approval to US drug maker Pfizer Inc.'s COVID-19 pill, the heath minister said Thursday, as the country struggles to slow fast-spreading omicron infections. The approval came less than a month after Pfizer applied in mid-January, an exceptional speed in a country where foreign drug approvals usually take much longer. Health Minister Shigeyuki Goto said the availability of Pfizer's Paxlovid pill gives high-risk patients, including elderly people and those with underlying health issues, greater treatment options. The approval comes as surging cases among elderly patients are starting to overwhelm hospitals in Tokyo and other metropolitan areas, and delayed booster vaccinations have reached only about 8% of the population. Most of Japan's 47 prefectures are currently under a mild version of a state of emergency. On Friday, Prime Minister Fumio Kishida announced plans to extend current restrictions in Tokyo and 12 other areas for three more weeks until Mar
The results underscore a comeback for GSK in the race to help fight the Covid-19 pandemic after it failed to bring a vaccine to the market so far
On Tuesday, the company revealed its fourth quarter earnings and revenue projections for 2022 where it said it estimates it will earn up to $102 billion in sales next year, which would be a new record
Pfizer said Tuesday that it expects adjusted earnings in the new year to range from USD 6.35 to USD 6.55 per share on USD 98 billion to USD 102 billion in revenue
Drug firm Pfizer said its net profit increased by 1.89 per cent to Rs 143.91 crore for the third quarter ended December 31, 2021.
France says it will start administering Pfizer's coronavirus antiviral drug this week, the first pill for treating Covid-19 approved in the 27-nation EU.
The request for emergency authorisation comes as the highly contagious Omicron variant has led to record numbers of infections